Exonic

High-Level Overview

Exonic is an AI-native platform revolutionizing drug discovery by crowdsourcing the process through an open, meritocratic global network. It offers a no-code synthetic biology engineering platform called Exonic Studio, where users can build, share, and run complex AI-driven workflows for designing and evaluating biological molecules such as DNA, RNA, proteins, and small molecules. This approach democratizes drug discovery, breaking down traditional silos and secrecy in biopharma by enabling worldwide collaboration and leveraging open-source AI models[1][3][5].

For an investment firm, Exonic’s mission centers on unlocking millions of drug discovery scientists globally by providing accessible, cutting-edge AI tools that accelerate biological research and drug development. Their investment philosophy likely emphasizes backing transformative biotech and AI innovations that disrupt entrenched industries. Key sectors include AI in drug discovery, synthetic biology, bioinformatics, and preclinical contract research. Exonic’s impact on the startup ecosystem is significant as it fosters an open, collaborative community that could accelerate innovation cycles and reduce barriers for biotech startups and researchers[1][2][5].

For a portfolio company, Exonic builds a drug discovery platform serving researchers, biotech companies, and AI scientists. It solves the problem of slow, secretive, and costly drug discovery by enabling rapid, collaborative design and validation of biological molecules using AI workflows without coding expertise. The company has demonstrated early growth momentum through successful public tournaments that experimentally validate user-generated designs, showing superior performance to existing benchmarks[1][5].

Origin Story

Exonic was founded in 2025 in San Francisco and quickly joined Y Combinator’s Fall 2025 batch[2]. The founder, Ben, envisioned creating the first drug discovery pipeline open to everyone worldwide, inspired by the availability of open-source biological AI models contrasted with the traditionally siloed, secretive nature of drug discovery institutions[1]. The founding team includes Chief Scientific Officer Mikhail Kulak, Ph.D., a molecular biologist with over 20 years of experience in cancer research and molecular biology, bringing deep domain expertise to the venture[1].

The idea emerged from the recognition that while AI models in biology are increasingly open, drug discovery remains locked behind closed doors. Early traction came from launching Exonic Studio, which allows users to build and share AI workflows without coding, and running public design tournaments that validate top submissions experimentally, proving the platform’s potential to crowdsource effective drug discovery[1][5].

Core Differentiators

• Open, Meritocratic Model: Unlike traditional secretive drug discovery, Exonic operates as an open tournament platform where anyone can contribute and compete, democratizing access to drug discovery[1].
• No-Code AI Workflows: Exonic Studio enables users to combine and run powerful open-source AI models visually, lowering the barrier to entry for complex biological design[1][5].
• Integrated Experimental Validation: The platform supports submitting top designs for wet-lab testing, closing the loop between computational design and real-world results[5].
• Cutting-Edge AI Models: Hosts state-of-the-art open-source bio AI models (e.g., Malinois, OpenFold2) and proprietary models, enabling advanced molecular design and evaluation[5].
• Collaborative Ecosystem: Users can share, fork, and improve workflows, fostering a vibrant community of AI drug discovery researchers worldwide[1][5].
• Expert Leadership: Guided by leaders in bio AI and molecular biology, ensuring scientific rigor and innovation[1].

Role in the Broader Tech Landscape

Exonic rides the convergence of several powerful trends: the rise of open-source AI in biology, the growing importance of synthetic biology and bioinformatics, and the increasing demand for faster, cheaper drug discovery. The timing is critical as AI models have matured, and the biotech industry seeks to break free from slow, costly, and closed R&D processes. Market forces such as the expanding AI drug discovery market (~$1.5B), bioinformatics (~$10B), synthetic biology (~$16B), and preclinical CRO services (~$79.5B global market) create a fertile environment for Exonic’s software-first, collaborative approach[5].

By turning the internet into a drug discovery powerhouse, Exonic influences the broader ecosystem by enabling startups, researchers, and institutions to accelerate innovation through shared AI tools and experimental feedback. This could reshape how biotech innovation is conducted, making it more inclusive, transparent, and rapid[1][5].

Quick Take & Future Outlook

Exonic is poised to expand its platform capabilities by supporting deeper research, coding, and AI model training, further empowering its community. Future trends shaping its journey include advances in AI-driven molecular design, increased adoption of no-code tools in biotech, and growing demand for collaborative, open science models. As Exonic scales, it may evolve into a central hub for AI-powered drug discovery, potentially disrupting traditional pharma R&D and accelerating the path from molecule design to validated therapeutics.

Its influence will likely grow as it attracts more users, integrates more sophisticated AI models, and expands experimental validation capacity, reinforcing its mission to democratize and accelerate drug discovery worldwide[1][5]. This aligns with its founding vision of flipping biopharma on its head by harnessing collective intelligence and open innovation.